121 related articles for article (PubMed ID: 16545740)
1. Continuing trials of GDNF in Parkinson's disease.
Barker RA
Lancet Neurol; 2006 Apr; 5(4):285-6. PubMed ID: 16545740
[No Abstract] [Full Text] [Related]
2. GDNF in treatment of Parkinson's disease: response to editorial.
Lang AE; Langston JW; Stoessl AJ; Brodsky M; Brooks DJ; Dhawan V; Elias WJ; Lozano AM; Moro E; Nutt JG; Stacy M; Turner D; Wooten GF
Lancet Neurol; 2006 Mar; 5(3):200-2. PubMed ID: 16488373
[No Abstract] [Full Text] [Related]
3. GDNF in treatment of Parkinson's disease: response to editorial.
Penn RD; Dalvi A; Slevin J; Young B; Gash D; Gerhardt G; Hutchinson M
Lancet Neurol; 2006 Mar; 5(3):202-3. PubMed ID: 16488374
[No Abstract] [Full Text] [Related]
4. Reply: GDNF poses troubling questions for doctors, drug maker.
Slevin JT; Gerhardt GA; Smith CD; Gash DM; Young AB
Ann Neurol; 2006 Jun; 59(6):989-90. PubMed ID: 16718700
[No Abstract] [Full Text] [Related]
5. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
Lindvall O; Wahlberg LU
Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
[TBL] [Abstract][Full Text] [Related]
6. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
Yasuhara T; Shingo T; Date I
Acta Med Okayama; 2007 Apr; 61(2):51-6. PubMed ID: 17471304
[TBL] [Abstract][Full Text] [Related]
7. GDNF therapy for Parkinson's disease.
Hong M; Mukhida K; Mendez I
Expert Rev Neurother; 2008 Jul; 8(7):1125-39. PubMed ID: 18590482
[TBL] [Abstract][Full Text] [Related]
8. Neurotrophic factor therapy for Parkinson's disease.
Rangasamy SB; Soderstrom K; Bakay RA; Kordower JH
Prog Brain Res; 2010; 184():237-64. PubMed ID: 20887879
[TBL] [Abstract][Full Text] [Related]
9. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
Whone AL; Boca M; Luz M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
J Parkinsons Dis; 2019; 9(2):301-313. PubMed ID: 30829619
[TBL] [Abstract][Full Text] [Related]
10. MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF).
Chebrolu H; Slevin JT; Gash DA; Gerhardt GA; Young B; Given CA; Smith CD
Exp Neurol; 2006 Apr; 198(2):450-6. PubMed ID: 16455079
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the role of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
Kakoty V; Sarathlal KC; Kaur P; Wadhwa P; Vishwas S; Khan FR; Alhazmi AYM; Almasoudi HH; Gupta G; Chellappan DK; Paudel KR; Kumar D; Dua K; Singh SK
Neurol Sci; 2024 Apr; 45(4):1409-1418. PubMed ID: 38082050
[TBL] [Abstract][Full Text] [Related]
12. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
13. Emerging restorative treatments for Parkinson's disease.
Deierborg T; Soulet D; Roybon L; Hall V; Brundin P
Prog Neurobiol; 2008 Aug; 85(4):407-32. PubMed ID: 18586376
[TBL] [Abstract][Full Text] [Related]
14. GDNF in Parkinson's disease: the perils of post-hoc power.
Matcham J; McDermott MP; Lang AE
J Neurosci Methods; 2007 Jul; 163(2):193-6. PubMed ID: 17540454
[TBL] [Abstract][Full Text] [Related]
15. Neurotrophic factors as a therapeutic target for Parkinson's disease.
Evans JR; Barker RA
Expert Opin Ther Targets; 2008 Apr; 12(4):437-47. PubMed ID: 18348680
[TBL] [Abstract][Full Text] [Related]
16. GDNF and protection of adult central catecholaminergic neurons.
Pascual A; Hidalgo-Figueroa M; Gómez-Díaz R; López-Barneo J
J Mol Endocrinol; 2011 Jun; 46(3):R83-92. PubMed ID: 21357726
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease.
Lapchak PA; Gash DM; Collins F; Hilt D; Miller PJ; Araujo DM
Exp Neurol; 1997 Jun; 145(2 Pt 1):309-21. PubMed ID: 9217068
[No Abstract] [Full Text] [Related]
18. GDNF poses troubling questions for doctors, drug maker. Toxicity, negative outcome raise doubts.
Ann Neurol; 2006 Mar; 59(3):A5-6. PubMed ID: 16489612
[No Abstract] [Full Text] [Related]
19. GDNF in Parkinson disease: an object lesson in the tyranny of type II.
Hutchinson M; Gurney S; Newson R
J Neurosci Methods; 2007 Jul; 163(2):190-2. PubMed ID: 16876872
[TBL] [Abstract][Full Text] [Related]
20. Assessment of GDNF in primate models of Parkinson's disease: comparison with human studies.
Eslamboli A
Rev Neurosci; 2005; 16(4):303-10. PubMed ID: 16519007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
